AKYA AKOYA BIOSCIENCES INC

Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024

Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024

MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2024 after the market close on May 13th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call are required to . It is recommended to register at least a day in advance. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at .

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit .

Investor Contact:

Priyam Shah

Media Contact:

Christine Quern



EN
22/04/2024

Underlying

AKYAAKOYA BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AKOYA BIOSCIENCES INC

 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences Opens Operations and Manufacturing Center of Excelle...

Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts MARLBOROUGH, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: AKYA), The Spatial Biology Company®, has opened its Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts to meet the accelerating demand for its spatial biology solutions and the increased utilization of the company’s PhenoCycler®-Fusion and the PhenoImager® HT platforms. “Spatial biology is transforming drug discovery, translational sciences, and clinical research, and advancing our ability to un...

May 6, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulator...

Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows KR-HT5 is based on Akoya’s PhenoImager® HT Platform MARLBOROUGH, Mass. and SHANGHAI, China, May 02, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, and Shanghai KR Pharmtech, a leading company providing molecular diagnostic solutions in China, have jointly announced that KR-HT5, which Akoya Biosciences co-developed with Shanghai KR Pharmtech utilizing the PhenoImager HT...

May 2, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024

Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024 MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the first quarter of 2024 after the market close on May 13th, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to . It is recommended to register at least a day in advance. A live and archived we...

April 22, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annu...

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10. In addition, the company will showcase new applications of it...

April 5, 2024 1 EN
 PRESS RELEASE
Free
AKYA AKOYA BIOSCIENC...

Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provide...

Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook Q4 2023 revenue $26.5 million and FY 2023 revenue $96.6 millionGuiding FY 2024 revenue range $114.0-118.0 million and operating cash flow breakeven by YE 2024 MARLBOROUGH, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2023. “Akoya's successful 2023 performance reflects the high demand for our leading spatial biology...

March 4, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch